Teva: This One Is Difficult (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical or Mylan: Which Has the Better Debt Profile?
Why You Should Still Buy Teva (NYSE:TEVA) | Seeking Alpha
Price-fixing lawsuit deals another blow to already fragile Teva, experts say | The Times of Israel
Teva Raises $2.1 Billion in Debt Tender Offer | Ctech
Teva Reports Fourth Quarter and Full Year 2019 Financial Results | Business Wire
Is Teva Pharmaceuticals a Brilliant Contrarian Pick? | The Motley Fool
Israel's Teva pharmaceuticals keeps selling to Russia despite sanctions - The Jerusalem Post
Teva Pharmaceutical: Past Behind And A Promising 2023 (NYSE:TEVA) | Seeking Alpha
Teva Avoids Bankruptcy, Huge Upside (NYSE:TEVA) | Seeking Alpha
Fitch downgrades Teva debt - Globes
Why It Is Time To Load Up On Teva Stock (NYSE:TEVA) | Seeking Alpha
Teva Sells $15 Billion of Bonds - WSJ
Teva Pharmaceutical to sell assets such as women's health unit to cut debt | Mint
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
Institutions Have Been Holding Back, but Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Beginning to Stabilize
Israel's Teva pharmaceuticals keeps selling to Russia despite sanctions - The Jerusalem Post
Federal data reveals extent of Teva's role in fueling US opioid crisis | The Times of Israel
Teva Posts 2021 Earnings and Puts Opioid Litigation in Rearview Mirror | BioSpace
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Teva earnings: Facing down cheaper generic prices, generic competition of its own and a lot of debt - MarketWatch
Teva shares approach 20-year low amid Moody's warning and other woes | Fierce Pharma
Why Teva's Stock Could Crash Another 50% | BioSpace
